CD274 and neoplasm: The combined immunotherapeutic effect of PMA-NeoV with anti-programmed cell death ligand 1 antibody (aPD-L1) or with the phosphatidylinositol 3‐kinase γ (PI3Kγ) inhibitor IPI-549 was further tested in MC38 mouse tumor model.